The first product-liability trial for Pfizer’s COX-2 inhibitor Celebrex has been set for June 6 in Alabama state court, The Wall Street Journal reports.
The plaintiff, Rosie Ware, alleges that Celebrex caused her 2005 stroke.
The drug is the only one in its class still on the market, a fact that could pose a serious hurdle for her attorneys, the Journal notes.
Suits for Bextra, which was withdrawn last April, could be harder to defend.
More than 200 federal cases for the two drugs have been consolidated before Judge Charles Breyer of US District Court for the Northern District of California. Pfizer put a “black-box” warning on Celebrex in August, following an FDA recommendation, stating that the drug may increase the risk of cardiovascular events, including heart attack and stroke.
Safety concerns have hurt sales, which fell 48% last year to $1.73 billion.